People: Nephros Inc (NEPH.OB)

NEPH.OB on OTC BB

0.73USD
16 May 2013
Price Change (% chg)

$-0.02 (-2.67%)
Prev Close
$0.75
Open
$0.66
Day's High
$0.75
Day's Low
$0.63
Volume
21,759
Avg. Vol
4,468
52-wk High
$2.95
52-wk Low
$0.63

Search Stocks

Summary

Name Age Since Current Position

James Scibetta

 47 2008 Independent Chairman of the Board

John Houghton

 48 2012 President, Chief Executive Officer

Gerald Kochanski

 58 2010 Chief Financial Officer

Paul Mieyal

 2012 Director

Arthur Amron

 56 2007 Independent Director

Lawrence Centella

 70 2001 Independent Director
» Insider Trading

Biographies

Name Description

James Scibetta

 Mr. James S. Scibetta serves as an Independent Chairman of the Board of Nephros Inc. He has served as a director of the company since November 2007 and as Chairman of the Board since September 2008. Since August 2008, Mr. Scibetta has been the Chief Financial Officer of Pacira Pharmaceuticals, Inc. Prior to that, Mr. Scibetta was Chief Financial Officer of Bioenvision, Inc. from December 2006 until its acquisition by Genzyme, Inc. in October 2007. From September 2001 to November 2006, Mr. Scibetta was Executive Vice President and CFO of Merrimack Pharmaceuticals, Inc., and he was a member of the Board of Directors of Merrimack from April 1998 to March 2004. Mr. Scibetta formerly served as a senior investment banker at Shattuck Hammond Partners, LLC and PaineWebber Inc., providing capital acquisition, mergers and acquisitions, and strategic advisory services to healthcare companies. From 2001 to 2008, Mr. Scibetta served as a member of the Board of Directors and Audit Committee Chairman of Labopharm, Inc. (Nasdaq: DDSS). Mr. Scibetta holds a B.S. in Physics from Wake Forest University, and an M.B.A. in Finance from the University of Michigan. He completed executive education studies in the Harvard Business School Leadership & Strategy in Pharmaceuticals and Biotechnology program.

John Houghton

 Mr. John C. Houghton has been appointed as President, Chief Executive Officer of Nephros, Inc., effective April 20, 2012. Mr. Houghton has over 25 years of commercialization experience in the pharmaceutical and medical device fields. He has direct experience in building out global commercial organizations including marketing, sales, sales operations, customer service, business analytics and new product development and has also been directly responsible for licensing products and joint ventures and partnerships. Mr. Houghton most recently served as President and CEO of CorMedix Inc. (NYSE-Amex: CRMD), a pharmaceutical company focused on therapeutic products for the treatment of cardio-renal disease. While President and CEO, Mr. Houghton led the acquisition of the company’s product candidates and the completion of its initial public offering. Prior to assuming the role of President and CEO, he was the Chief Business Officer for CorMedix. Before joining CorMedix, Mr. Houghton established the global sales and marketing infrastructure for the Biotech division of Stryker Corp. (NYSE: SYK). Prior to Stryker, he worked with Aventis (NYSE: SNY) and predecessor companies for more than 14 years. During his time at Aventis he led the global marketing of Nasacort, served as commercial lead on the Aventis-Millennium inflammation collaboration, and functioned as the global new products commercialization head for respiratory, inflammation, cardiovascular, and metabolism products. Mr. Houghton received his B.Sc. from Liverpool John Moores University, United Kingdom.

Gerald Kochanski

 Mr. Gerald J. Kochanski serves as Chief Financial Officer of Nephros Inc. Mr. Kochanski has served as Chief Financial Officer since April 2008 and served as acting Chief Executive Officer from March 31 through April 5, 2010. Prior to joining the company, Mr. Kochanski served as the Financial Services Director of Lordi Consulting LLC, a national consulting firm, from February 2007 through February 2008. From October 2004 until December 2006, Mr. Kochanski was the Chief Financial Officer of American Water Enterprises, Inc., a business unit of a privately owned company in the water and wastewater treatment industry. From November 1998 through September 2004, Mr. Kochanski was the Chief Financial Officer of Scanvec Amiable Ltd., a publicly traded provider of software to the signmaking, digital printing and engraving industries. Mr. Kochanski is a Certified Public Accountant and received his B.S. in Accounting and his M.B.A. in Finance from La Salle University, where he also serves as an adjunct School of Business faculty member.

Paul Mieyal

 Dr. Paul A. Mieyal, Ph.D., serves as Director of Nephros Inc. He resigned as Acting Chief Executive Officer of the company on April 20, 2012. Dr. Mieyal has been a Vice President of Wexford Capital LP since October 2006. From January 2000 through September 2006, he was Vice President in charge of healthcare investments for Wechsler & Co., Inc., a private investment firm and registered broker-dealer. In his employment with Wexford and Wechsler, Dr. Mieyal has worked closely with both private and public pharmaceutical and other healthcare companies, advising them on regulatory development, corporate and financial matters. Dr. Mieyal is also a director of Nile Therapeutics, Inc., which is a publicly traded companies. Dr. Mieyal received his Ph.D. in pharmacology from New York Medical College, a B.A. in chemistry and psychology from Case Western Reserve University, and is a Chartered Financial Analyst.

Arthur Amron

 Mr. Arthur H. Amron serves as an Independent Director of Nephros Inc., since September 2007. Mr. Amron has served as a director of company since September 2007. Mr. Amron is a partner of Wexford Capital LP, a position he has held since 1999, and serves as its General Counsel, a position he has held since joining Wexford in 1994. Mr. Amron also actively participates in various private equity transactions, particularly in the bankruptcy and restructuring areas, and has served on the boards and creditors’ committees of a number of public and private companies in which Wexford has held investments. From 1991 to 1994, Mr. Amron was an Associate at Schulte Roth & Zabel LLP, specializing in corporate and bankruptcy law, and from 1984 to 1991, Mr. Amron was an Associate at Debevoise & Plimpton LLP specializing in corporate litigation and bankruptcy law. Mr. Amron holds a JD from Harvard University, a BA in political theory from Colgate University and is a member of the New York Bar.

Lawrence Centella

 Mr. Lawrence J. Centella serves as an Independent Director of Nephros Inc., since January 2001. Mr. Centella has served as a director of the company since January 2001. Mr. Centella serves as president of Renal Patient Services, LLC, a company that owns and operates dialysis centers, and has served in such capacity since June 1998. From 1997 to 1998, Mr. Centella served as executive vice president and chief operating officer of Gambro Healthcare, Inc., an integrated dialysis company that manufactured dialysis equipment, supplied dialysis equipment and operated dialysis clinics. From 1993 to 1997, Mr. Centella served as president and chief executive officer of Gambro Healthcare Patient Services, Inc. (formerly REN Corporation). Prior to that, Mr. Centella served as president of COBE Renal Care, Inc., Gambro Hospal, Inc., LADA International, Inc. and Gambro, Inc. Mr. Centella is also the founder of LADA International, Inc. Mr. Centella received a B.S. from DePaul University.

Basic Compensation

Name Fiscal Year Total

James Scibetta

 --

John Houghton

 --

Gerald Kochanski

 370,193

Paul Mieyal

 28,880

Arthur Amron

 --

Lawrence Centella

 --
As Of 30 Dec 2011

Options Compensation

Name Options Value

James Scibetta

 0 0

John Houghton

 0 0

Gerald Kochanski

 0 0

Paul Mieyal

 0 0

Arthur Amron

 0 0

Lawrence Centella

 0 0

Insider Trading

» Full list on Insider Trading
Search Stocks